Yaqiong Liu1, Li Lin2, Zijian Huang1, Bing Ji1, Shanshan Mei1, Ying Lin3, Zhuanxing Shen1. 1. Department of Obstetrics and Gynecology, Guangzhou Women and Children Medical Center, Guangzhou Medical University Affiliated Women and Children Medical Center Guangzhou 510120, China. 2. Department of Obstetrics and Gynecology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University Shenzhen 518000, China. 3. Department of Obstetrics and Gynecology, People's Hospital of Hunan Province Changsha 410005, China.
Abstract
AIMS: To investigate the expression and clinical significance of flotillin-2 (FLOT2) in cervical cancer (CC). METHODS: We examined FLOT2 mRNA levels in 10 pairs of cervical cancer and adjacent normal tissues. Immunohistochemistry was performed to analyze FLOT2 protein expression in 115 archived cervical cancer samples. The association between FLOT2 levels, clinicopathologic factors and prognosis was analyzed statistically as well. RESULTS: The cancer tissues of CC patients had clearly increased expression of FLOT2 at mRNA level as compared to adjacent nontumorous tissues. Survival analysis of CC patients indicated that FLOT2 expression was significantly associated with poor overall and local recurrence-free survival (P = 0.025 and P = 0.028, respectively). Moreover, FLOT2 expression was significantly correlated with clinical stage, tumor differentiation, and lymph nodes metastasis. Multivariate analysis revealed that FLOT2 expression was an independent prognostic factor for overall survival in CC patients. CONCLUSION: FLOT2 may serve as an oncogene in the development of CC, and may serve as a clinicopathologic biomarker for prognosis in CC patients.
AIMS: To investigate the expression and clinical significance of flotillin-2 (FLOT2) in cervical cancer (CC). METHODS: We examined FLOT2 mRNA levels in 10 pairs of cervical cancer and adjacent normal tissues. Immunohistochemistry was performed to analyze FLOT2 protein expression in 115 archived cervical cancer samples. The association between FLOT2 levels, clinicopathologic factors and prognosis was analyzed statistically as well. RESULTS: The cancer tissues of CC patients had clearly increased expression of FLOT2 at mRNA level as compared to adjacent nontumorous tissues. Survival analysis of CC patients indicated that FLOT2 expression was significantly associated with poor overall and local recurrence-free survival (P = 0.025 and P = 0.028, respectively). Moreover, FLOT2 expression was significantly correlated with clinical stage, tumor differentiation, and lymph nodes metastasis. Multivariate analysis revealed that FLOT2 expression was an independent prognostic factor for overall survival in CC patients. CONCLUSION:FLOT2 may serve as an oncogene in the development of CC, and may serve as a clinicopathologic biomarker for prognosis in CC patients.
Authors: Parul Hazarika; Marya F McCarty; Victor G Prieto; Saira George; Daniel Babu; Dimpy Koul; Menashe Bar-Eli; Madeleine Duvic Journal: Cancer Res Date: 2004-10-15 Impact factor: 12.701